CoreRx, Inc. announces the expansion of it’s capabilities including DEA licensure for controlled substances. This gives CoreRx, Inc. the ability to work with DEA schedule 2-5 active pharmaceutical ingredients and drug products. CoreRx also announces the addition of stability storage chambers at four ICH guideline storage conditions of 4°C, 25°C/60%R.H., 30°C/65%R.H. and 40°C/75%R.H. The stability chambers will enable CoreRx, Inc. to offer both non-GMP and GMP stability study capabilities to their clients.